Download PDF
Pharmacopsychiatry 2005; 38(2): 105-106
DOI: 10.1055/s-2005-837815
Letter
© Georg Thieme Verlag KG Stuttgart · New York

Risperidone-associated Transient Diabetic Ketoacidosis and Diabetes Mellitus Type 1 in a Patient Treated with Valproate and Lithium

A Case ReportB. Mithat1 , T. Alpaslan2 , C. Bulent3 , T. Cengiz4
  • 1Associated Professor, Departments of Endocrinology, University of Dicle, School of Medicine, Diyarbakir, Turkey
  • 2Assistant Professor, Departments of Endocrinology, University of Dicle, School of Medicine, Diyarbakir, Turkey
  • 3Research Fellow, Internal Medicine, University of Dicle, School of Medicine, Diyarbakir, Turkey
  • 4Assistant Professor, Biochemistry, University of Dicle, School of Medicine, Diyarbakir, Turkey
Further Information

Publication History

Received: 20.3.2004 Revised: 16.6.2004

Accepted: 31.8.2004

Publication Date:
02 March 2005 (online)

Also available at
    Permissions and Reprints

A 37-year-old man treated with valproate and lithium for bipolar affective disorder since 1999 and with risperidone since March 2003 was admitted to our clinic due to metabolic acidosis. Serum glucose was 647 mg/dL and urine ketones were positive. The patient was accepted as diabetic ketoacidosis (DKA). Risperidone, valproate, and lithium were immediately stopped, and the patient was treated with insulin and IV fluid replacement. Serum insulin and C-peptide levels were too low, and islet cell antibody and anti-GAD antibody were positive. We accepted him as type 1 diabetes mellitus (DM type 1). After the intensive treatment of diabetes, insulin requirements decreased gradually and diabetes mellitus disappeared completely within three months. Conclusion: Risperidone may lead to transient DM type 1 and DKA.

References

  • 1 Ananth J, Venkatesh R, Burgoyne K, Gunatilake S. Atypical antipsychotic drug use and diabetes.  Psychother Psychosom. 2002;  71 (5) 244-254
    PubMedGoogle Scholar
  • 2 Baptista T, Kin N M, Beaulieu S, de Baptista E A. Obesity and related metabolic abnormalities during antipsychotic drug administration: mechanisms, management and research perspectives.  Pharmacopsychiatry. 2002;  35 (6) 205-19
    Article in Thieme ConnectPubMedGoogle Scholar
  • 3 Cohen D. Atypical antipsychotics and new onset diabetes mellitus - an overview of the literature.  Pharmacopsychiatry. 2004;  37 (6) 1-11
    Article in Thieme ConnectPubMedGoogle Scholar
  • 4 Croarkin P E, Jacobs K M, Bain B K. Diabetic ketoacidosis associated with risperidone treatment?.  Psychosomatics. 2000;  41 369-370
    CrossrefPubMedGoogle Scholar
  • 5 Gitlin M. Lithium and the kidney: an updated review.  Drug Saf.. 1999;  20 (3) 231-43
    PubMedGoogle Scholar
  • 6 Haupt D W, Newcomer J W. Risperidone-associated diabetic ketoacidosis.  Psychosomatics. 2001;  42 (3) 279-80
    CrossrefPubMedGoogle Scholar
  • 7 Jin H, Meyer J M, Jeste D V. Phenomenology of and risk factors for new-onset diabetes mellitus and diabetic ketoacidosis associated with atypical antipsychotics: an analysis of 45 published cases.  Ann Clin Psychiatry. 2002;  14 (1) 59-64
    CrossrefPubMedGoogle Scholar

Mithat Bahceci, MD

Dicle Universiti Tip Fakultesi

Endokrinoloji BD

21280 Diyarbakir-Turkey

Phone: +90 412 2488001

Fax: +90 412 2488520

Email: mbahceci@dicle.edu.tr

      >